Farhang Alem, Interim Director of the Biomedical Research Laboratory, Institute for Biohealth Innovation, received funding for: “PRNT Analysis of Samples from Athari BioSciences.”
Researchers with the Biomedical Research Laboratory will perform Plaque Reduction Neutralization Tests (PRNTs) on Athari patient serum samples with parameters defined by Athari. They will also produce and deliver a report containing all patient serum sample titer results for SARS-CoV-2.
PRNT analysis is a serological test that utilizes the ability of a specific antibody to neutralize a virus, and in turn, prevent the virus from causing the formation of plaques in a cell monolayer.
Alem received $28,786 from Athari BioSciences for this research. Funding began in March 2024 and will end in late February 2025.
###
ABOUT GEORGE MASON UNIVERSITY
George Mason University is Virginia’s largest public research university. Located near Washington, D.C., Mason enrolls more than 40,000 students from 130 countries and all 50 states. Mason has grown rapidly over the past half-century and is recognized for its innovation and entrepreneurship, remarkable diversity, and commitment to accessibility. In 2023, the university launched Mason Now: Power the Possible, a one-billion-dollar comprehensive campaign to support student success, research, innovation, community, and stewardship. Learn more at gmu.edu.